Candida Research Today is a free monthly online journal that collates and summarizes the latest research about Candida, including details on thrush infections, yeast, diet, treatment, symptoms.

The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y, Edwards JE

Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502, USA. bspellberg@labiomed.org

We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.

Published 22 August 2005 in Infect Immun, 73(9): 6191-3.
Full-text of this article is available online (may require subscription).

© 2004-2008 Candida Research Today. All Rights Reserved.